Repare Therapeutics Inc. (NASDAQ:RPTX – Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 1,130,000 ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

CRSP Boasts Encouraging CRISPR-Based Pipeline Programs CRISPR Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. Management is developing two next ...

Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past ... the company is yet to record revenues from its sales. Also, a lack of pipeline updates beyond Casgevy’s approval is not ...